联合免疫检查点阻断治疗后转移性皮肤鳞状细胞癌的完全病理缓解及同种异体移植排斥反应 - Suppr

Suppr

超能文献

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.

作者信息

Miller David M, Faulkner-Jones Beverly E, Stone James R, Drews Reed E

机构信息

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2017 Sep 8;3(5):412-415. doi: 10.1016/j.jdcr.2017.06.005. eCollection 2017 Sep.

DOI:10.1016/j.jdcr.2017.06.005

PMID:28932782

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5594230/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/5594230/838b6b4c1df1/gr1.jpg

相似文献

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.

JAAD Case Rep. 2017 Sep 8;3(5):412-415. doi: 10.1016/j.jdcr.2017.06.005. eCollection 2017 Sep.

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.

Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.

Cancer Immunol Res. 2019 Mar;7(3):458-465. doi: 10.1158/2326-6066.CIR-18-0226. Epub 2019 Jan 11.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.

Oncologist. 2019 Nov;24(11):1416-1419. doi: 10.1634/theoncologist.2018-0686. Epub 2019 Aug 23.

Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.

Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8.

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.

J Immunother Cancer. 2019 Dec 4;7(1):338. doi: 10.1186/s40425-019-0801-z.

Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.

Cancer Chemother Pharmacol. 2018 May;81(5):823-827. doi: 10.1007/s00280-018-3557-0. Epub 2018 Mar 3.

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.

JAAD Case Rep. 2021 Oct 20;18:23-25. doi: 10.1016/j.jdcr.2021.10.009. eCollection 2021 Dec.

引用本文的文献

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.

Cancers (Basel). 2024 Apr 10;16(8):1452. doi: 10.3390/cancers16081452.

Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.

EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024.

Update on the Molecular Pathology of Cutaneous Squamous Cell Carcinoma.

Int J Mol Sci. 2023 Apr 2;24(7):6646. doi: 10.3390/ijms24076646.

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations.

Dermatol Pract Concept. 2021 Nov 1;11(Suppl 2):e2021170S. doi: 10.5826/dpc.11S2a170S. eCollection 2021 Nov.

Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Interdiscip Sci. 2021 Dec;13(4):801-814. doi: 10.1007/s12539-021-00437-4. Epub 2021 Jun 21.

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).

J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001664.

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Int J Mol Sci. 2020 Dec 6;21(23):9300. doi: 10.3390/ijms21239300.

Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

Curr Oncol. 2020 Aug;27(4):e399-e407. doi: 10.3747/co.27.6015. Epub 2020 Aug 1.

Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.

J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000908.

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.

Int J Mol Sci. 2020 Apr 22;21(8):2956. doi: 10.3390/ijms21082956.

本文引用的文献

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.

N Engl J Med. 2017 Jan 12;376(2):191-192. doi: 10.1056/NEJMc1614298.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol. 2016 Dec;34(34):4102-4109. doi: 10.1200/JCO.2016.67.2477. Epub 2016 Oct 31.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.

Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.

Br J Dermatol. 2016 Dec;175(6):1382-1386. doi: 10.1111/bjd.14642. Epub 2016 Oct 17.

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

N Engl J Med. 2016 Mar 3;374(9):896-8. doi: 10.1056/NEJMc1509268.

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.

JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.

作者信息

Miller David M, Faulkner-Jones Beverly E, Stone James R, Drews Reed E

机构信息

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2017 Sep 8;3(5):412-415. doi: 10.1016/j.jdcr.2017.06.005. eCollection 2017 Sep.

DOI:10.1016/j.jdcr.2017.06.005

PMID:28932782

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5594230/

Abstract

摘要

相似文献

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.

JAAD Case Rep. 2017 Sep 8;3(5):412-415. doi: 10.1016/j.jdcr.2017.06.005. eCollection 2017 Sep.

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.

Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.

Cancer Immunol Res. 2019 Mar;7(3):458-465. doi: 10.1158/2326-6066.CIR-18-0226. Epub 2019 Jan 11.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.

Oncologist. 2019 Nov;24(11):1416-1419. doi: 10.1634/theoncologist.2018-0686. Epub 2019 Aug 23.

Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.

Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8.

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.

J Immunother Cancer. 2019 Dec 4;7(1):338. doi: 10.1186/s40425-019-0801-z.

Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.

Cancer Chemother Pharmacol. 2018 May;81(5):823-827. doi: 10.1007/s00280-018-3557-0. Epub 2018 Mar 3.

JAAD Case Rep. 2021 Oct 20;18:23-25. doi: 10.1016/j.jdcr.2021.10.009. eCollection 2021 Dec.

引用本文的文献

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.

Cancers (Basel). 2024 Apr 10;16(8):1452. doi: 10.3390/cancers16081452.

Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.

EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024.

Update on the Molecular Pathology of Cutaneous Squamous Cell Carcinoma.

Int J Mol Sci. 2023 Apr 2;24(7):6646. doi: 10.3390/ijms24076646.

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations.

Dermatol Pract Concept. 2021 Nov 1;11(Suppl 2):e2021170S. doi: 10.5826/dpc.11S2a170S. eCollection 2021 Nov.

Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Interdiscip Sci. 2021 Dec;13(4):801-814. doi: 10.1007/s12539-021-00437-4. Epub 2021 Jun 21.

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).

J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001664.

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Int J Mol Sci. 2020 Dec 6;21(23):9300. doi: 10.3390/ijms21239300.

Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

Curr Oncol. 2020 Aug;27(4):e399-e407. doi: 10.3747/co.27.6015. Epub 2020 Aug 1.

Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.

J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000908.

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.

Int J Mol Sci. 2020 Apr 22;21(8):2956. doi: 10.3390/ijms21082956.

本文引用的文献

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.

N Engl J Med. 2017 Jan 12;376(2):191-192. doi: 10.1056/NEJMc1614298.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol. 2016 Dec;34(34):4102-4109. doi: 10.1200/JCO.2016.67.2477. Epub 2016 Oct 31.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.

Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.

Br J Dermatol. 2016 Dec;175(6):1382-1386. doi: 10.1111/bjd.14642. Epub 2016 Oct 17.

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

N Engl J Med. 2016 Mar 3;374(9):896-8. doi: 10.1056/NEJMc1509268.

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.

JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.